Related Experiment Video
Updated: Feb 18, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk
Moshe Shashar1, Mostafa E Belghasem2, Shinobu Matsuura3
1Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
Insights
New research reveals how indolic solutes in chronic kidney disease (CKD) cause hyperthrombosis via the aryl hydrocarbon receptor (AHR) and tissue factor (TF) pathway, mediated by STIP1 homology and U-box-containing protein 1 (STUB1). This offers a way to reduce clotting risks without increasing bleeding.
Area of Science:
- Nephrology
- Vascular Biology
- Biochemistry
Background:
- Chronic kidney disease (CKD) increases atherothrombosis risk and bleeding complications.
- Mechanisms linking uremic solutes, vascular proteins (tissue factor [TF], aryl hydrocarbon receptor [AHR]), and thrombosis/bleeding risks are unclear.
- Indolic uremic solutes are implicated in CKD-related vascular dysfunction.
Purpose of the Study:
- To elucidate the mechanisms by which indolic solutes drive hyperthrombosis in CKD.
- To investigate the role of the aryl hydrocarbon receptor (AHR) and tissue factor (TF) in this process.
- To identify potential therapeutic targets for managing thrombotic risks in CKD without affecting hemostasis.
Main Methods:
- Development of an indolic solute-specific animal model for CKD.
- Investigation of AHR- and TF-dependent pathways.
- Analysis of STIP1 homology and U-box-containing protein 1 (STUB1) as a ubiquitin ligase regulating TF.
- Inhibition of STUB1 in vascular smooth muscle cells and assessment of thrombosis and bleeding in flow loops.
- Human studies correlating STUB1 and TF expression in uremic vessels.
Main Results:
- Indolic solutes mediate a hyperthrombotic phenotype in CKD via an AHR- and TF-dependent mechanism.
- AHR regulates TF through STUB1, a ubiquitin ligase that degrades TF via ubiquitination in the uremic environment.
- Human uremic vessels show an inverse relationship between STUB1 and TF expression and reduced STUB1-TF interaction.
- STUB1 manipulation in vascular smooth muscle cells inhibited thrombosis without prolonging bleeding time.
- STUB1 perturbations reversed the uremic hyperthrombotic phenotype, unlike heparin.
Conclusions:
- STUB1 acts as a key mediator in the indolic solute-AHR-TF axis, refining the understanding of CKD thrombosis.
- Targeting STUB1 offers a novel strategy to mitigate hyperthrombosis in CKD without compromising hemostatic balance.
- This approach presents a promising therapeutic avenue for CKD patients facing both thrombotic and bleeding risks.
Abstract:
Chronic kidney disease (CKD/uremia) remains vexing because it increases the risk of atherothrombosis and is also associated with bleeding complications on standard antithrombotic/antiplatelet therapies. Although the associations of indolic uremic solutes and vascular wall proteins [such as tissue factor (TF) and aryl hydrocarbon receptor (AHR)] are being defined, the specific mechanisms that drive the thrombotic and bleeding risks are not fully understood. We now present an indolic solute-specific animal model, which focuses on solute-protein interactions and shows that indolic solutes mediate the hyperthrombotic phenotype across all CKD stages in an AHR- and TF-dependent manner. We further demonstrate that AHR regulates TF through STIP1 homology and U-box-containing protein 1 (STUB1). As a ubiquitin ligase, STUB1 dynamically interacts with and degrades TF through ubiquitination in the uremic milieu. TF regulation by STUB1 is supported in humans by an inverse relationship of STUB1 and TF expression and reduced STUB1-TF interaction in uremic vessels. Genetic or pharmacological manipulation of STUB1 in vascular smooth muscle cells inhibited thrombosis in flow loops. STUB1 perturbations reverted the uremic hyperthrombotic phenotype without prolonging the bleeding time, in contrast to heparin, the standard-of-care antithrombotic in CKD patients. Our work refines the thrombosis axis (STUB1 is a mediator of indolic solute-AHR-TF axis) and expands the understanding of the interconnected relationships driving the fragile thrombotic state in CKD. It also establishes a means of minimizing the uremic hyperthrombotic phenotype without altering the hemostatic balance, a long-sought-after combination in CKD patients.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:16Clot Retraction and Fibrinolysis
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...